
|Videos|May 18, 2023
ER+, HER2- Advanced Breast Cancer: Clinical Implications of the EMERALD Trial
Following their discussion of the EMERALD trial and elacestrant with Virginia Kaklamani, MD, DSc, the Oncology Brothers share clinical implications of the EMERALD trial to practice and look toward the future of ER+, HER2- advanced breast cancer management.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Indefinite Myeloma Maintenance Shows No OS Benefit vs 2-Year Duration
2
Allogeneic CD70 CAR T-Cell Therapy Shows Activity in Refractory Kidney Cancer
3
Pembrolizumab Plus Denosumab Shows Activity in Pretreated Kidney Cancer
4
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
5


























